rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PPBT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update

      IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A): Investigational New Drug (IND) application submission planned during 2027, followed by a first-in-human study IM1240 data to be presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 REHOVOT, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize

      Nov 17Yahoo FinancePPBT
      Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
      Oct 29Yahoo FinancePPBT
      Purple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle

      Detailed price information for Purple Biotech Ltd ADR (PPBT-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailPPBT
      Crude Oil Moves Higher; US Factory Orders Rise In July
      Sep 2BenzingaCRDOPPBTTCRX
      Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection

      Purple Biotech (NASDAQ:PPBT) has received a U. S.

      Sep 2Yahoo FinancePPBT
      Why Is Purple Biotech Stock Gaining Wednesday?
      Sep 2BenzingaPPBT
      Top Midday Gainers

      Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a "Notice of

      Sep 2Yahoo FinancePPBT
      New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
      Sep 2Yahoo FinancePPBT
      Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

      Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3...

      Aug 28BarchartPPBT
      Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

      Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific...

      Aug 28BarchartPPBT

      This is the newest page. Registered accounts read further back.